Short answer
Cogent Biosciences, Inc. (COGT) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$111M
- −37.7% YoY · −15.6% QoQ
- EPS (diluted)
- −$0.60
- −20.0% YoY · −15.4% QoQ
Source: XBRL data from the Cogent Biosciences, Inc. (COGT) Q3 2026 10-Q on SEC EDGAR. USD.
Cogent Biosciences, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, no product sales; net loss $111.4M vs $80.9M YoY
- Operating margin not applicable, operating loss $117.2M vs $83.4M YoY
- R&D expense $75.1M, G&A $42.1M, versus $69.0M and $14.4M YoY
- Cash, equivalents and securities $791.1M; operating cash outflow $244.9M for nine months
- U.S. launch targeted second half 2026, pending approval; liquidity expected through late 2028
Risk Factors
- No material changes from the December 31, 2025 Form 10-K risk factors filed February 17, 2026
- Carried-forward risks may materially adversely affect business, financial condition, or operating results
- Additional unknown or currently immaterial risks could materially affect results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cogent Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.